Group One Trading
GNCA

Group One Trading’s Genocea Biosciences, Inc. GNCA Stock Holding History

Group One Trading’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-69,400
Closed -$81K – 9192
2021
Q4 		$81K Buy
69,400
+45,100
+186% +$67.2K ﹤0.01% 5920
2021
Q3 		$47K Sell
24,300
-22,400
-48% -$44.1K ﹤0.01% 6594
2021
Q2 		$109K Buy
46,700
+36,500
+358% +$88K ﹤0.01% 5861
2021
Q1 		$28K Sell
10,200
-73,000
-88% -$216K ﹤0.01% 6607
2020
Q4 		$201K Sell
83,200
-67,900
-45% -$155K ﹤0.01% 4056
2020
Q3 		$346K Buy
+151,100
New +$396K ﹤0.01% 3186
2020
Q2 		– Sell
-1,500
Closed -$3K – 6534
2020
Q1 		$3K Buy
1,500
+500
+50% +$1.01K ﹤0.01% 4938
2019
Q4 		$2K Hold
1,000
– – ﹤0.01% 4945
2019
Q3 		$3K Buy
+1,000
New +$3.41K ﹤0.01% 4896
2017
Q4 		– Sell
-125
Closed -$1K – 5495
2017
Q3 		$1K Buy
+125
New +$4.74K ﹤0.01% 4738
2017
Q2 		– Sell
-150
Closed -$7K – 5334
2017
Q1 		$7K Buy
+150
New +$5.86K ﹤0.01% 4226

Other funds holding GNCA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Group One Trading's GNCA Position: Q2 2022 in Review

Group One Trading sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 50,517 shares — an estimated $63K sold.

Group One Trading first reported a position in GNCA in Q2 2018 and held it in 11 quarters. The position peaked at $118K in Q3 2021. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

  • Group One Trading reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
  • Group One Trading sold 50,517 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $63K.
  • Group One Trading first reported a position in Genocea Biosciences, Inc. in Q2 2018 and held it in 11 quarters.
  • Group One Trading's Genocea Biosciences, Inc. position peaked at $118K in Q3 2021.
  • 5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on Group One Trading's 13F filing for Q2 2022, filed 11 Aug 2022.